by Jonathan P. Gertler and Peter Bak
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.
Language
🇺🇲
Publishing Since
6/2/2021
Email Addresses
1 available
Phone Numbers
0 available
February 7, 2025
<p>In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and Vasilios Kofitsas, Partner and Managing Director of Investment Banking at Back Bay Life Science Advisors, review the performance of the healthcare markets in 2024, offering insights into what 2025 could bring. With a detailed analysis of market trends, IPO activities, and investor behaviors, they evaluate the past year's challenges and the cautious optimism prevailing in the sector as the new year unfolds. As well, there's an emphasis on the importance of European investor engagement for companies looking to list in the U.S. market.</p><p><br></p><p><br>Learn more about the DNB//Back Bay Partnership and read our disclosures <a href="https://www.bblsa.com/dnb-back-bay-partnership">here</a>.</p>
November 8, 2024
<p>The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic.<br> <br>To date, there have been ten bispecific antibody approvals in oncology, seven of which are for hematological malignancies. Recently, there has been more traction in development pipelines for solid tumors. Most bispecific antibody approvals are currently or projected to be above the $1M annual revenue threshold.<br> <br>Podcast topics include:<br> <br> • The biologics of a bispecific antibody<br> • The benefits of a bispecific antibody compared to autologous therapies<br> • The buzz around Akeso and Summit’s PD-1 VEGF bispecific antibody asset<br> • The broad state of bispecifics in approved products and development pipelines<br> • The potential of trispecifics, bispecific conjugates and beyond</p>
September 30, 2024
<p>In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis points. </p><p><br></p><p>Topics in the podcast include: </p><ul><li>After two difficult years, the appearance of a healthy market rotation since July </li><li>The Fed’s decision mid-September to cut rates by 50 basis points </li><li>Healthcare IPOs: historical and recent activity – is the window opening?</li><li>An outlook including headwinds and tailwinds that may impact the healthcare sector</li></ul><p>We welcome listener questions and/or topics you’d like to learn more about.</p><p><br></p><p>You can listen to previous episodes <a href="https://www.bblsa.com/podcasts">here</a> or submit your inquiries <a href="mailto:[email protected]">here</a>.</p><p><br></p><p>Learn more about the DNB//Back Bay Partnership and read our disclaimers at <a href="https://www.bblsa.com/dnb-back-bay-partnership">https://www.bblsa.com/dnb-back-bay-partnership</a>.</p>
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more
BioCentury
Matt Pillar
STAT
Biotech 2050
The Wall Street Journal
The New York Times
New York Times Opinion
Barstool Sports
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.